Gufic BioSciences Share Price

Pharmaceuticals company Gufic BioSciences announced Q4FY26 & FY26 results Consolidated Financial Highlights: Consolidated Total Income for Q4FY26 stood at Rs 25,064.59 lakh, representing a QoQ increase of 7.94% compared to Rs 23,220.04 lakh in Q3FY26 and a YoY increase of 22.02% from Rs 20,541.46 lakh in Q4FY25. Consolidated Revenue from operations for Q4FY26 was Rs 25,181.97 lakh, showing a QoQ growth of 8.82% from Rs 23,140.99 lakh and a YoY growth of 22.83% from Rs 20,502.01 lakh. Consolidated Net Profit for Q4FY26 was recorded at Rs 2,189.61 lakh, a significant QoQ increase of 76.24% from Rs 1,242.36 lakh and a YoY increase of 183.64% from Rs 771.95 lakh in Q4FY25. Consolidated Revenue from operations for the full year FY26 reached Rs 94,400.66 lakh, marking a 15.15% increase from Rs 81,980.59 lakh in FY25. Consolidated Total Income for FY26 was Rs 94,666.40 lakh, an increase of 14.97% compared to Rs 82,343.24 lakh in FY25. The Consolidated Net Profit for the full year FY26 stood at Rs 6,421.27 lakh, showing a decrease of 7.80% compared to Rs 6,964.87 lakh in FY25. Consolidated Total Comprehensive Income for FY26 was Rs 6,471.40 lakh, compared to Rs 6,952.18 lakh in FY25. Standalone Financial Results: Standalone Total Income for Q4FY26 was Rs 25,085.65 lakh, registering a QoQ increase of 8.18% from Rs 23,188.68 lakh and a YoY increase of 22.13% from Rs 20,540.31 lakh. Standalone Revenue from operations for Q4FY26 stood at Rs 25,205.23 lakh, up 9.07% QoQ from Rs 23,109.36 lakh and up 22.94% YoY from Rs 20,502.01 lakh. The company reported a Standalone Net Profit of Rs 2,057.44 lakh in Q4FY26, representing a QoQ growth of 32.19% from Rs 1,556.39 lakh and a YoY growth of 158.00% compared to Rs 797.41 lakh in Q4FY25. For the full year FY26, Standalone Revenue from operations reached Rs 94,047.54 lakh, a 14.72% YoY increase from Rs 81,980.59 lakh in FY25. Standalone Total Income for FY26 was Rs 94,305.75 lakh, up 14.53% from Rs 82,342.09 lakh in FY25. Standalone Net Profit for the full year FY26 was Rs 6,314.87 lakh, a decline of 9.70% from Rs 6,993.28 lakh in FY25. Standalone Total Comprehensive Income for FY26 was Rs 6,364.80 lakh, compared to Rs 6,980.51 lakh in FY25. Business Highlights: Segment-wise Performance: The Group's business activity falls within a single operating segment, which is Pharmaceuticals. Dividend Recommendation: The Board of Directors has recommended a final dividend of Re 0.10/- per equity share (i.e., @ 10% on the face value of Rs 1/- each) for FY26, subject to shareholder approval. Auditor Opinion: The Statutory Auditors have issued an Audit Report with an unmodified opinion on the Audited Financial Results (Standalone and Consolidated) for FY26. Tax Concession: During the year, the company opted for the concessional tax regime under section 115BAA of the Income Tax Act, 1961, and consequently restated the deferred tax assets/liabilities on account of change in tax rates. Result PDF

• Trendlyne
• 9 hours 19 minutes ago

Conference Call with Gufic BioSciences Management and Analysts on Q3FY26 Performance and Outlook. Listen to the full earnings transcript.

• Trendlyne
• 3 months 1 week ago

Pharmaceuticals company Gufic BioSciences announced Q3FY26 results Total Income: Rs 231.1 crore against Rs 230.4 crore during Q3FY25, change 0%. EBITDA: Rs 37.1 crore against Rs 37.9 crore during Q3FY25, change -2%. EBITDA Margin: 16.05% for Q3FY26. PBT: Rs 21.1 crore against Rs 20.5 crore during Q3FY25, change 3%. PBT Margin: 9.13% for Q3FY26. PAT: Rs 15.6 crore against Rs 14.9 crore during Q3FY25, change 5%. PAT Margin: 6.75% for Q3FY26. Result PDF

• Trendlyne
• 3 months 1 week ago